Stockscreener 앱 받기
5.985
0.42%
-0.025
시간 외 거래:
5.99
0.005
+0.08%
전일 마감가:
$6.01
열려 있는:
$6.01
하루 거래량:
6,275
Relative Volume:
0.71
시가총액:
$83.11M
수익:
$57.94M
순이익/손실:
$-2.34M
주가수익비율:
-35.92
EPS:
-0.1666
순현금흐름:
$3.82M
1주 성능:
+0.08%
1개월 성능:
+2.05%
6개월 성능:
-7.92%
1년 성능:
+3.19%
1일 변동 폭
$5.85
$6.1624
1주일 범위
$5.7601
$6.1624
52주 변동 폭
$5.50
$9.6299
Champions Oncology Inc Stock (CSBR) Company Profile
명칭
Champions Oncology Inc
전화
410-369-0365
주소
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
5.985 | 83.46M | 57.94M | -2.34M | 3.82M | -0.1666 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-09-12 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2019-11-18 | 개시 | The Benchmark Company | Speculative Buy |
Champions Oncology Inc 주식(CSBR)의 최신 뉴스
Champions Oncology (CSBR) Q1 2026 Earnings: EPS Misses by Wide Margin as Company Posts LossTrading Community Hub - Newser
Champions Oncology, Inc.Common Stock (NQ: CSBR - The Chronicle-Journal
In Vivo CRO Market Size is Poised to be Valued at USD 11.83 - GlobeNewswire
Champions Onc (CSBR) Declines -1.48% Amid Market Weakness 2026-05-19Community Breakout Alerts - Newser
(CSBR) Risk Channels and Responsive Allocation - Stock Traders Daily
Champions Onc (CSBR) Q1 2026 Earnings Miss: EPS $-0.02 vs $0.09 ExpectedSocial Signal Watchlist - Newser
Champions Onc (CSBR) Q1 2026 Results Fall Short — EPS $-0.02, Revenue $N/AShort Squeeze - newser.com
Heartland Express, Inc. 8-K SEC Filing Details for May 14, 2026 – Company Information, Stock, and Compliance - Minichart
Qumulo Champions Olivia Newton-John Cancer Research Institute in New “Imagine” Fundraising Campaign - Business Wire
Cizzle Bio CEO Bill Behnke Participates in National Oncology Commercialization Panel at City of Hope's 25th Ci4CC Summit - PR Newswire
Europe Stocks: Research Stocks from Europe Stock Market - GuruFocus
(CSBR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Leading Companies Enhancing Their Presence in the Tumor Models Market - openPR.com
Patient-Derived Xenograft (PDX) Models Market (2026-2033) | - openPR.com
Champions Oncology (NASDAQ:CSBR) Shares Cross Below 200-Day Moving AverageWhat's Next? - MarketBeat
Celebration of Champions event held for children affected by cancer - fox5sandiego.com
Liquidity Mapping Around (CSBR) Price Events - Stock Traders Daily
Champions Onc (CSBR) Stock: Is It Forming a Pattern (Market Focus) 2026-04-27On Balance Volume - Newser
Champions Oncology (CSBR) Proxy Filing Summary - Quartr
Champions Oncology (NASDAQ:CSBR) Share Price Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Radiopharmaceuticals Market Size to Exceed USD 15.21 Billion By 2035 Rising Cancer Cases Boost the Market Demand - Dailyhunt
Data4Cure Presents a Foundation Model for Forward and Reverse Translation at AACR 2026 Annual Meeting - Scott Coop
Elisrasib Demonstrates High DCR in KRAS G12C+ NSCLC - The ASCO Post
Elisrasib Demonstrates High Disease Control Rate in KRAS G12C–Mutant NSCLC - The ASCO Post
Champions Onc (CSBR) Stock: Growth vs Risks (-0.98%) 2026-04-18Community Breakout Alerts - Xã Châu Thành
Cavco Industries Jumps 7.1% Amid Sector-Wide Selling - AlphaStreet
Why (CSBR) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Champions Oncology (NASDAQ:CSBR) Stock Crosses Above Fifty Day Moving AverageShould You Sell? - MarketBeat
Patient Derived Xenograft/PDX Models Market Size Expanding - openPR.com
Aug Decliners: How does Champions Oncology Inc compare to its peersMarket Activity Report & Growth Focused Investment Plans - baoquankhu1.vn
Aug Catalysts: What is Champions Oncology Incs debt to equity ratio2026 Macro Moves & Consistent Return Investment Signals - baoquankhu1.vn
Chipmakers Recap: Should I average down on ACMR stockWeekly Profit Recap & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Comedian Michael Kosta Headlines Karmanos Comedy Champions - PR Newswire
CSBR Should I Buy - Intellectia AI
Champions Oncology to present eight studies at AACR meeting By Investing.com - Investing.com Australia
Champions Oncology to present eight studies at AACR meeting - Investing.com
Champions Oncology to Present New Data on Predicting Response and Resistance at AACR 2026 - ACCESS Newswire
Eight cancer studies from Champions Oncology focus on drug response, resistance - Stock Titan
Bond Watch: Can Champions Oncology Inc weather a recessionWeekly Trading Summary & Verified Technical Signals - baoquankhu1.vn
Patient Derived Xenograft (PDX) Models Market is estimated - openPR.com
How does Champions Oncology Inc compare to its peers2026 Biggest Moves & Growth-Oriented Investment Plans - baoquankhu1.vn
Fennec Pharmaceuticals Inc. (FENC) stock price, news, quote and history - Yahoo Finance UK
CSBR Forecast, Price Target & Analyst Ratings | CHAMPIONS ONCOLOGY INC (NASDAQ:CSBR) - ChartMill
Understanding Momentum Shifts in (CSBR) - Stock Traders Daily
Performance Recap: What is Champions Oncology Incs debt to equity ratioMarket Risk Summary & Community Trade Idea Sharing - baoquankhu1.vn
CSBR Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Market Review: How correlated is Champions Oncology Inc to the S P5002026 Setups & Long-Term Capital Growth Strategies - baoquankhu1.vn
Global Tumor Models Market Set to Soar from $2.37B in 2026 - GlobeNewswire
Datavault AI Inc. (NASDAQ: DVLT) and Demora Foundation Execute Technology Integration Agreement to Power the K-Entertainment & K-Wave Global Platform - STT Info
CSBR PE Ratio & Valuation, Is CSBR Overvalued - Intellectia AI
Datavault AI Returns a Second Time for Exclusive Investor Forum at Mar-a-Lago - NTB Kommunikasjon
Champions Oncology Inc (CSBR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):